Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

135.02 -13.32 (-8.98%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	655,489
Open	146.60
Bid (Size)	131.61 (100)
Ask (Size)	151.18 (400)
Prev. Close	148.34
Today's Range	131.30 - 146.60
52wk Range	18.23 - 151.18
Shares Outstanding	98,935,025
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Palvella Therapeutics Announces Pricing of Upsized Public Offering

February 25, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces Proposed Public Offering

February 24, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Performance

YTD	+34.6%	+34.6%
1 Month	+64.9%	+64.9%
3 Month	+42.8%	+42.8%
6 Month	+156.2%	+156.2%
1 Year	+597.1%	+597.1%

More News

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

February 24, 2026

Via Chartmill

Tuesday's session: top gainers and losers ↗

February 24, 2026

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

February 24, 2026

Via Chartmill

Which stocks are moving before the opening bell on Tuesday? ↗

February 24, 2026

Via Chartmill

Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗

February 24, 2026

Via Stocktwits

Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

February 24, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

February 23, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies

January 09, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis

February 02, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs

January 07, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

January 05, 2026

Via Chartmill

Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas

December 16, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No

December 15, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Q3 2025 Earnings Miss, Highlights Key Clinical Milestones ↗

November 11, 2025

Via Chartmill

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 11, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

November 06, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

November 05, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Earnings Scheduled For November 11, 2025 ↗

November 11, 2025

Via Benzinga

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

November 04, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

October 13, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

September 24, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

September 17, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

September 15, 2025

From Palvella Therapeutics Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Palvella Therapeutics, Inc. - Common Stock publicly traded?

Yes, Palvella Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Palvella Therapeutics, Inc. - Common Stock trade on?

Palvella Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Palvella Therapeutics, Inc. - Common Stock?

The ticker symbol for Palvella Therapeutics, Inc. - Common Stock is PVLA on the Nasdaq Stock Market

What is the current price of Palvella Therapeutics, Inc. - Common Stock?

The current price of Palvella Therapeutics, Inc. - Common Stock is 135.02

When was Palvella Therapeutics, Inc. - Common Stock last traded?

The last trade of Palvella Therapeutics, Inc. - Common Stock was at 02/27/26 04:00 PM ET

What is the market capitalization of Palvella Therapeutics, Inc. - Common Stock?

The market capitalization of Palvella Therapeutics, Inc. - Common Stock is 13.36B

How many shares of Palvella Therapeutics, Inc. - Common Stock are outstanding?

Palvella Therapeutics, Inc. - Common Stock has 13B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.